Estramustine
Emcyt (estramustine) is a small molecule pharmaceutical. Estramustine was first approved as Emcyt on 1982-01-01. It is used to treat prostatic neoplasms in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Emcyt
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Estramustine phosphate sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EMCYT | Pharmacia & Upjohn | N-018045 RX | 1982-01-01 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| emcyt | New Drug Application | 2018-12-19 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
76 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | G89.18 | — | — | — | 3 | 2 | 5 | |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | 1 | 1 | 3 | 5 |
| Tachycardia | D013610 | HP_0001649 | R00.0 | — | 1 | — | 1 | 2 | 4 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 2 | 1 | 3 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 1 | 1 | 2 |
| Injection site reaction | D000075662 | — | 1 | 1 | 1 | — | 2 | ||
| Hypotension | D007022 | EFO_0005251 | I95 | — | 1 | — | 1 | — | 2 |
| Coronary artery disease | D003324 | I25.1 | — | — | 1 | 1 | — | 2 | |
| Cholelithiasis | D002769 | EFO_0004799 | K80 | — | — | — | 1 | — | 1 |
| Drug overdose | D062787 | — | — | — | 1 | — | 1 |
Show 18 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Septic shock | D012772 | A48.3 | — | 7 | 2 | — | 2 | 10 | |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | 1 | — | — | 2 |
| Intracranial aneurysm | D002532 | EFO_0003870 | I67.1 | — | — | 2 | — | — | 2 |
| Diabetic foot | D017719 | EFO_1001459 | 1 | 1 | 1 | — | — | 2 | |
| Cerebral arterial diseases | D002539 | EFO_1000859 | — | — | 1 | — | — | 1 | |
| Anesthesia | D000758 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | 1 | — | — | — | 4 | ||
| Cognitive dysfunction | D060825 | G31.84 | 1 | 1 | — | — | 1 | 2 | |
| Blood pressure | D001794 | EFO_0004325 | — | 1 | — | — | — | 1 | |
| Heart rate | D006339 | EFO_0004326 | — | 1 | — | — | — | 1 | |
| Intervertebral disc displacement | D007405 | EFO_1001800 | — | 1 | — | — | — | 1 | |
| Ovarian cysts | D010048 | HP_0000138 | N83.1 | 1 | 1 | — | — | — | 1 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 1 | — | — | — | 1 |
| Myocardial reperfusion injury | D015428 | EFO_0002687 | 1 | 1 | — | — | — | 1 | |
| Traumatic brain injuries | D000070642 | S06 | 1 | 1 | — | — | — | 1 | |
| Primary dysautonomias | D054969 | 1 | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peripheral arterial disease | D058729 | EFO_0004265 | 1 | — | — | — | — | 1 | |
| Aging | D000375 | GO_0007568 | R41.81 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 2 | 2 |
| Sepsis | D018805 | A41.9 | — | — | — | — | 2 | 2 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | — | 1 | 1 | |
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | — | — | 1 | 1 |
| Cerebral hemorrhage | D002543 | — | — | — | — | 1 | 1 | ||
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | — | — | 1 | 1 | |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | — | — | 1 | 1 |
| Controlled hypotension | D007023 | — | — | — | — | 1 | 1 | ||
| Patient satisfaction | D017060 | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ESTRAMUSTINE |
| INN | estramustine |
| Description | Estramustine is a carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid. It has a role as an antineoplastic agent, an alkylating agent and a radiation protective agent. It is a carbamate ester, a 17beta-hydroxy steroid and an organochlorine compound. It is functionally related to a 17beta-estradiol. |
| Classification | Small molecule |
| Drug class | estrogens; antineoplastics (chloroethylamine derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2O |
Identifiers
| PDB | — |
| CAS-ID | 2998-57-4 |
| RxCUI | 4089 |
| ChEMBL ID | CHEMBL1575 |
| ChEBI ID | 4868 |
| PubChem CID | 259331 |
| DrugBank | DB01196 |
| UNII ID | 35LT29625A (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,307 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
427 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more